Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors

FEBS Letters

Volumn 579, Issue 6, 2005, Pages 1389-1393

  Iwashita, Akinori ^a   Hattori, Kouji ^a   Yamamoto, Hirofumi ^a   Ishida, Junya ^a   Kido, Yoshiyuki ^a   Kamijo, Kazunori ^a   Murano, Kenji ^a   Miyake, Hiroshi ^a   Kinoshita, Takayoshi ^b   Warizaya, Masaichi ^b   Ohkubo, Mitsuru ^b   Matsuoka, Nobuya ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b Exploratory Research Laboratories   (Japan)

Author keywords

Poly(ADP ribose) polymerase 1; Poly(ADP ribose) polymerase 2; SBDD

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; QUINAZOLINONE DERIVATIVE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

EID: 20044393463     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2005.01.036     Document Type: Article

References (20)

1. S.W. Yu, H. Wang, M.F. Poitras, C. Coombs, W.J. Bowers, H.J. Federoff, G.G. Poirier, T.M. Dawson, and V.L. Dawson Mediation of poly(ADP-ribose) polymerase-1 dependent cell death by apoptosis-inducing factor Science 297 2002 259 263
2. C. Szabo, and V.L. Dawson Role of poly(ADP-ribose)synthetase in inflammation and ischemia-reperfusion Trends Pharmacol. Sci. 19 1998 287 298
3. W.M. Shieh, J.C. Ame, M.V. Wilson, Z.Q. Wang, and D.W. Koh Poly(ADP-ribose)polymerase null mouse cells synthesize ADP-ribose polymerase J. Biol. Chem. 273 1998 30069 30072
4. J.C. Ame, V. Rolli, V. Schreiber, C. Niedergang, F. Apiou, P. Decker, S. Muller, T. Hoger, J. Menissier-de Murcia, and G. De Murcia PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose)polymerase J. Biol. Chem. 274 1999 17860 17868
5. + binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling Biochemistry 37 1998 3893 3900
6. A. Ruf, J.M. Murcia, G.M. Murcia, and G.E. Schulz Structure of the catalytic fragment of poly(ADP-ribose) polymerase from chicken Proc. Natl. Acad. Aci. USA 93 1996 7481 7485
7. A.W. Oliver, J.C. Ame, S.M. Roe, V. Good, G. DeMurcia, and L.H. Pearl Crystal structure of the catalytic fragment of murine poly Nucleic Acids Res. 32 2004 456 464
8. G. De Murcia, V. Schreiber, M. Molinate, B. Saulier, O. Poch, M. Masson, C. Niedergang, and J. Menissier Structure and function of poly(ADP-ribose) polymerase Mol. Cell Biochem. 138 1994 15 24
9. T. Kinoshita, I. Nakanishi, M. Warizaya, A. Iwashita, Y. Kido, K. Hattori, and T. Fujii Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase FEBS Lett. 556 2004 43 46
10. A. Iwashita, S. Yamazaki, K. Mihara, K. Hattori, H. Yamamoto, J. Ishida, N. Matsuoka, and S. Mutoh Neuroprotective effects of a novel poly(ADP-ribose)polymerase-1 inhibitor,2-{3-[4-(4-chlorophenyl)-1-piperazinyl] propyl}-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease J. Pharmacol. Exp. Ther. 309 2004 1067 1078
11. Recent reviews on PARP inhibitors: Peukert, S., Schwahn, U. (2004) New inhibitors of poly(ADP-ribose)polymerase (PARP). Expert Opin. Ther. Pat. 14, 1531-1551
12. K. Hattori, Y. Kido, H. Yamamoto, J. Ishida, K. Kamijo, K. Murano, M. Ohkubo, T. Kinoshita, A. Iwashita, K. Mihara, S. Yamazaki, N. Matsuoka, Y. Teramura, and H. Miyake Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase J. Med. Chem. 47 2004 4151 4154
13. A. Iwashita, K. Mihara, S. Yamazaki, S. Matsuura, J. Ishida, H. Yamamoto, K. Hattori, N. Matsuoka, and S. Mutoh A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice J. Pharmacol. Exp. Ther. 310 2004 1114 1124
14. T. Kinoshita, T. Tsutsumi, R. Maruki, M. Warizaya, Y. Ishii, and T. Fujii Cloning, expression, purification, crystallization and preliminary diffraction analysis of the C-terminal catalytic domain of human poly(ADP-ribose) polymerase Acta Crystallogr. D60 2004 109 111
15. Collaborative Computational Project, Number 4, The CCP4 suite: Programs for Protein Crystallography (1994) Acta Crystallogr. D50, 760-763
16. K. Ogata, and H. Umeyama An automatic homology modeling method consisting of database searches and simulated annealing J. Mol. Graphics Mod. 18 2000 258 272
17. S.S. Canan Koch, L.H. Thoresen, J.G. Tikhe, K.A. Maegley, R.J. Almassy, J. Li, X.-H. Yu, S.E. Zook, R.A. Kumpf, C. Zhang, T.J. Boritzki, R.N. Mansour, K.E. Zhang, A. Ekker, C.R. Calabrese, N.J. Curtin, S. Kyle, H.D. Thomas, L.-Z. Wang, A.H. Calvert, B.T. Golding, R.J. Griffin, D.R. Newell, S. Webber, and Z. Hostomsky Novel tricyclic poly(ADP-ribose)polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure J. Med. Chem. 45 2002 4961 4974
18. A.W. White, R. Almassy, A.H. Calvert, N.J. Curtin, R.J. Griffin, Z. Hostomsky, K. Maegley, D.R. Newell, S. Srinivasan, and B.T. Golding Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase J. Med. Chem. 43 2000 4084 4097
19. In X-ray crystallography of 5 and PARP-1, the side chain of Glu763 in PARP-1 was also restricted by a hydrogen bond with neighbor amino acid
20. In murine PARP-2, the replacement of Gln308 by Lys308 was observed. The side chain of Lys308 is also not restricted; see in Ref. [6]